TB and Tobacco | Tobacco cessation within TB programmes: A ‘real world’ solution for countries with dual burden of disease

Summary
We aim to reduce the burden of tobacco-related lung diseases. Our approach is to integrate inexpensive tobacco cessation strategies of proven efficacy into TB control programmes. This has three advantages: a) Preventing non-communicable diseases as well as reducing TB-related deaths; b) TB patients are more likely to quit tobacco than healthy smokers – ‘teachable moments’; and c) in the absence of specialist infrastructure, an approach to ‘piggyback’ cessation on existing programmes is a desirable policy imperative.
We will first assess the effectiveness and cost-effectiveness of tobacco cessation strategies in helping TB patients to quit and improving their TB outcomes - the effectiveness goal; and then explore how best these strategies can be delivered, sustained and scaled-up – the implementation goal. We propose six work packages for Bangladesh, Nepal and Pakistan - high TB and tobacco burden countries.
WP1 Development & Feasibility: To optimise the delivery of tobacco cessation strategies within TB programmes (focus group discussions [FGD], interviews, surveys, expert panel workshops)
WP2 & 3 Effect and economic evaluation: To assess the effectiveness and cost effectiveness of cytisine with behavioural support vs. behavioural support alone on tobacco cessation and TB outcomes (randomised controlled trial [RCT])
WP4 Process evaluation: To study the design and delivery of the tobacco cessation strategies (FGD, observations, exit interviews)
WP5 Context evaluation: To study the influence of contextual factors on the RCT outcomes (lit. review, interviews, surveys, analysis)
WP6 Scale up & Sustainability: To assess sustainability of the cessation strategies and identify the likely costs, obstacles and opportunities for scaling these up (FGD, interviews, cost and outcomes analysis)
Our ambition is that by studying the ‘real world’ influences on the implementation and success of tobacco cessation we will be able to translate our findings into benefits for patients
Unfold all
/
Fold all
More information & hyperlinks
Web resources: https://cordis.europa.eu/project/id/680995
Start date: 01-11-2015
End date: 31-10-2019
Total budget - Public funding: 2 999 828,75 Euro - 2 999 828,00 Euro
Cordis data

Original description

We aim to reduce the burden of tobacco-related lung diseases. Our approach is to integrate inexpensive tobacco cessation strategies of proven efficacy into TB control programmes. This has three advantages: a) Preventing non-communicable diseases as well as reducing TB-related deaths; b) TB patients are more likely to quit tobacco than healthy smokers – ‘teachable moments’; and c) in the absence of specialist infrastructure, an approach to ‘piggyback’ cessation on existing programmes is a desirable policy imperative.
We will first assess the effectiveness and cost-effectiveness of tobacco cessation strategies in helping TB patients to quit and improving their TB outcomes - the effectiveness goal; and then explore how best these strategies can be delivered, sustained and scaled-up – the implementation goal. We propose six work packages for Bangladesh, Nepal and Pakistan - high TB and tobacco burden countries.
WP1 Development & Feasibility: To optimise the delivery of tobacco cessation strategies within TB programmes (focus group discussions [FGD], interviews, surveys, expert panel workshops)
WP2 & 3 Effect and economic evaluation: To assess the effectiveness and cost effectiveness of cytisine with behavioural support vs. behavioural support alone on tobacco cessation and TB outcomes (randomised controlled trial [RCT])
WP4 Process evaluation: To study the design and delivery of the tobacco cessation strategies (FGD, observations, exit interviews)
WP5 Context evaluation: To study the influence of contextual factors on the RCT outcomes (lit. review, interviews, surveys, analysis)
WP6 Scale up & Sustainability: To assess sustainability of the cessation strategies and identify the likely costs, obstacles and opportunities for scaling these up (FGD, interviews, cost and outcomes analysis)
Our ambition is that by studying the ‘real world’ influences on the implementation and success of tobacco cessation we will be able to translate our findings into benefits for patients

Status

CLOSED

Call topic

HCO-06-2015

Update Date

26-10-2022
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.3. Treating and managing disease
H2020-EU.3.1.3.0. Cross-cutting call topics
H2020-HCO-2015
HCO-06-2015 Global Alliance for Chronic Diseases. Prevention and treatment of lung diseases